Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
On April 15, 2018, Blueprint Medicines Corporation (the “Company”) issued a press release announcing data from its ongoing Phase 1 clinical trial evaluating BLU-667 for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors. The data were presented on Sunday, April 15, 2018 in an oral presentation during the clinical trials plenary session at the American Association for Cancer Research (“AACR”) Annual Meetingin Chicago, Illinois. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the AACR Annual Meetingis furnished as Exhibit 99.2 to this Current Report on Form 8-K.
In addition, on April 15, 2018, the Company hosted an investor event and live webcast to discuss the data presented at the AACR Annual Meeting. A copy of the presentation from the investor event is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.